Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, John B.A.G. Haanen, Helen Gogas
Topics & Concepts
NivolumabMedicineIpilimumabMelanomaImmune checkpointImmunotherapyCancer researchTumor microenvironmentImmune systemPembrolizumabImmunologyCancer Immunotherapy and BiomarkersCAR-T cell therapy researchMelanoma and MAPK Pathways